Trial Profile

Erlotinib (Tarceva) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
04 Sep 2013 Planned end date changed from 1 May 2015 to 1 Aug 2014 as reported by ClinicalTrials.gov.
04 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com